Azathioprine
VIDEO: ‘Highly treatable’ IgG4-related disease ‘rewarding’ to diagnose
In this video, John H. Stone, MD, MPH, professor of medicine at Harvard Medical School, the Edward A. Fox Chair in Medicine at Massachusetts General Hospital, discusses an important facet of IgG4-related disease other rheumatologists and providers should be aware of.
Mycophenolate ‘comparable, if not better’ than azathioprine for autoimmune hepatitis
PHILADELPHIA — Mycophenolate mofetil appeared to be more efficacious and tolerable than azathioprine in patients with autoimmune hepatitis, especially among those aged older than 50 years and with lower IgG levels, according to a presenter.
VIDEO: Treating autoimmune hepatitis with mycophenolate ‘still a cautionary tale’
PHILADELPHIA — In this video, Nancy S. Reau, MD, FAASLD, AGAF, speaks with Healio about findings from a systemic review and meta-analysis on the efficacy of mycophenolate mofetil compared with azathioprine for autoimmune hepatitis.
VIDEO: Mycophenolate surfaces as treatment for autoimmune hepatitis
PHILADELPHIA — In this video, Paul Kwo, MD, professor of medicine at Stanford University, discusses a plenary session about the “emerging role” of mycophenolate mofetil for the treatment of autoimmune hepatitis.
Mycophenolate mofetil induces remission in nearly 60% with autoimmune hepatitis
Mycophenolate mofetil was superior to azathioprine in achieving biochemical remission in treatment-naive patients with autoimmune hepatitis who were also treated with prednisolone, according to data presented at EASL Congress.
Central nervous system vasculitis treatment strategies still lack strong data
Current treatment strategies for patients with central nervous system vasculitis are not based on high-grade scientific evidence but rather expert opinion, according to a speaker at the Biologic Therapies Summit.
VIDEO: Combination therapy, tailoring regimen critical in vasculitis treatment
Severe infection risk for lupus lower with belimumab vs. oral immunosuppressants
PHILADELPHIA — Patients with non-renal systemic lupus erythematosus who receive belimumab demonstrate a lower risk for severe infection vs. those treated with oral immunosuppressants, according to data presented at ACR Convergence 2022.
Leflunomide noninferior to azathioprine as lupus nephritis maintenance therapy
Leflunomide is non-inferior to azathioprine in terms of safety and efficacy for lupus nephritis maintenance therapy, according to data published in the Annals of the Rheumatic Diseases.
No adverse childhood outcomes through 17 years after prenatal hydroxychloroquine exposure
Prenatal exposure to hydroxychloroquine in birthing parents with systemic lupus erythematosus results in no significant adverse outcomes in children from breast feeding through 17 years, according to data published in Rheumatology.